Filing Details

Accession Number:
0001179110-22-002947
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-10 17:05:03
Reporting Period:
2022-05-06
Accepted Time:
2022-05-10 17:05:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1551152 Abbvie Inc. ABBV Pharmaceutical Preparations (2834) 320375147
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1609447 Michael Severino 1 N. Waukegan Road
North Chicago IL 60064
Vice Chairman No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.01 Par Value Acquisiton 2022-05-06 74,309 $54.44 226,412 No 4 M Direct
Common Stock, $0.01 Par Value Acquisiton 2022-05-06 25,691 $54.86 252,103 No 4 M Direct
Common Stock, $0.01 Par Value Disposition 2022-05-06 40,176 $150.10 211,927 No 4 S Direct
Common Stock, $0.01 Par Value Disposition 2022-05-06 45,988 $151.13 165,939 No 4 S Direct
Common Stock, $0.01 Par Value Disposition 2022-05-06 13,836 $151.78 152,103 No 4 S Direct
Common Stock, $0.01 Par Value Acquisiton 2022-05-09 66,299 $54.86 218,402 No 4 M Direct
Common Stock, $0.01 Par Value Acquisiton 2022-05-09 33,701 $58.88 252,103 No 4 M Direct
Common Stock, $0.01 Par Value Disposition 2022-05-09 47,215 $149.53 204,888 No 4 S Direct
Common Stock, $0.01 Par Value Disposition 2022-05-09 31,714 $150.63 173,174 No 4 S Direct
Common Stock, $0.01 Par Value Disposition 2022-05-09 21,071 $151.42 152,103 No 4 S Direct
Common Stock, $0.01 Par Value Acquisiton 2022-05-10 70,779 $58.88 222,882 No 4 M Direct
Common Stock, $0.01 Par Value Acquisiton 2022-05-10 29,221 $61.36 252,103 No 4 M Direct
Common Stock, $0.01 Par Value Disposition 2022-05-10 22,873 $151.16 229,230 No 4 S Direct
Common Stock, $0.01 Par Value Disposition 2022-05-10 28,536 $152.24 200,694 No 4 S Direct
Common Stock, $0.01 Par Value Disposition 2022-05-10 48,591 $152.83 152,103 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (Right to Buy) Disposition 2022-05-06 74,309 $54.44 74,309 $54.44
Common Stock Option (Right to Buy) Disposition 2022-05-06 25,691 $54.86 25,691 $54.86
Common Stock Option (Right to Buy) Disposition 2022-05-09 66,299 $54.86 66,299 $54.86
Common Stock Option (Right to Buy) Disposition 2022-05-09 33,701 $58.88 33,701 $58.88
Common Stock Option (Right to Buy) Disposition 2022-05-10 70,779 $58.88 70,779 $58.88
Common Stock Option (Right to Buy) Disposition 2022-05-10 29,221 $61.36 29,221 $61.36
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-06-02 2024-06-01 No 4 M Direct
66,299 2017-02-18 2026-02-17 No 4 M Direct
0 2017-02-18 2026-02-17 No 4 M Direct
70,779 2016-02-19 2025-02-18 No 4 M Direct
0 2016-02-19 2025-02-18 No 4 M Direct
70,879 2018-02-16 2027-02-15 No 4 M Direct
Footnotes
  1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.58 to $150.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.58 to $151.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.58 to $151.95 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.04 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.04 to $151.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.04 to $151.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.55 to $151.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.55 to $152.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.55 to $153.50 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.